Effects of interferon-β on co-signaling molecules: Upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-β treatment in patients with multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 2, 2008, Pages 166-176

  Wiesemann, Elke ^a   Deb, Milani ^a   Trebst, Corinna ^a   Hemmer, Bernhard ^b   Stangel, Martin ^a   Windhagen, Anja ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

B7 family; co stimulatory molecules; interferon beta; multiple sclerosis; PD L1; PD L2

Indexed keywords

BETA1A INTERFERON; CD40 ANTIGEN; CD86 ANTIGEN; INTERFERON BETA SERINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; RECURRENCE RISK; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-BETA; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; STAT1 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 43149084182     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458507081342     Document Type: Article

References (52)

1. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
2. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
4. Paty DW, Li DK Interferon beta-lb is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. Neurology 2001; 57: S10-15.
5. Hartung HP, Bar-Or A., Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004; 251 (Suppl 5): v12-29.
6. Chitnis T., Khoury SJ Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J Allergy Clin Immunol 2003; 112: 837-49.
7. Greenwald RJ, Freeman GJ, Sharpe AH The B7 family revisited. Annu Rev Immunol 2005; 23: 515-48.
8. Racke MK, Ratts RB, Arredondo L., Perrin PJ, Lovett-Racke A. The role of costimulation in autoimmune demyelination. J Neuroimmunol 2000; 107: 205-15.
9. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe MN, Cuzner ML et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995; 182: 1985-96.
10. Windhagen A., Maniak S., Gebert A., Ferger I., Heidenreich F. Costimulatory molecules B7-1 and B7-2 on CSF cells in multiple sclerosis and optic neuritis. J Neuroimmunol 1999; 96: 112-20.
11. Monteyne P., Guillaume B., Sindic CJ B7-1 (CD80), B7-2 (CD86), interleukin-12 and transforming growth factor-beta mRNA expression in CSF and peripheral blood mononuclear cells from multiple sclerosis patients. J Neuroimmunol 1998; 91: 198-203.
12. Svenningsson A., Dotevall L., Stemme S., Andersen O. Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. J Neuroimmunol 1997; 75: 59-68.
13. Gerritse K., Laman JD, Noelle RJ, Aruffo A., Ledbetter JA, Boersma WJ et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996; 93: 2499-504.
14. Marckmann S., Wiesemann E., Hilse R., Trebst C., Stangel M., Windhagen A. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Clin Exp Immunol 2004; 138: 499-506.
15. Rottman JB, Smith T., Tonra JR, Ganley K., Bloom T., Silva R. et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001; 2: 605-11.
16. Sporici RA, Beswick RL, von Allmen C., Rumbley CA, Hayden-Ledbetter M., Ledbetter JA et al. ICOS ligand costimulation is required for T-cell encephalitogenicity. Clin Immunol 2001; 100: 277-88.
17. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003; 33: 2706-16.
18. Salama AD, Chitnis T., Imitola J., Ansari MJ, Akiba H., Tushima F. et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003; 198: 71-8.
19. Kroner A., Mehling M., Hemmer B., Rieckmann P., Toyka KV, Maurer M. et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005; 58: 50-7.
20. Schreiner B., Mitsdoerffer M., Kieseier BC, Chen L., Hartung HP, Weller M. et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004; 155: 172-82.
21. Pachner AR An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003; 61: 1444-6.
22. Hong J., Zang YC, Hutton G., Rivera VM, Zhang JZ Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol 2004; 152: 126-39.
23. Koike F., Satoh J., Miyake S., Yamamoto T., Kawai M., Kikuchi S. et al. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol 2003; 139: 109-18.
24. Sturzebecher S., Wandinger KP, Rosenwald A., Sathyamoorthy M., Tzou A., Mattar P. et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126: 1419-29.
25. Wiesemann E., Soenmez D., Heidenreich F., Windhagen A. Interferon beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells. J Neuroimmunol 2002; 123: 160-9.
26. Noronha A., Toscas A., Jensen MA Interferon beta decreases T-cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-53.
27. Wang X., Chen M., Wandinger KP, Williams G., Dhib-Jalbut S. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol 2000; 165: 548-7.
28. Genc K., Dona DL, Reder AT Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997; 99: 2664-71.
29. Liu Z., Pelfrey CM, Cotleur A., Lee JC, Rudick RA Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001; 112: 153-62.
30. Filion LG, Matusevicius D., Graziani-Bowering GM, Kumar A., Freedman MS Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis. Clin Immunol 2003; 106: 127-38.
31. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-69.
32. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-51.
33. Freeman GJ, Long AJ, Iwai Y., Bourque K., Chernova T., Nishimura H. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-34.
34. Latchman Y., Wood CR, Chernova T., Chaudhary D., Borde M., Chernova I. et al. PD-L2 is a second ligand for PD-1 and inhibits T-cell activation. Nat Immunol 2001; 2: 261-8.
35. Latchman YE, Liang SC, Wu Y., Chernova T., Sobel RA, Klemm M. et al. PD-L1-deficient mice show that PD-L1 on T-cells, antigen-presenting cells, and host tissues negatively regulates T-cells. Proc Natl Acad Sci USA 2004; 101: 10691-6.
36. Dong H., Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G. et al. Costimulating aberrant T-cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003; 111: 163-70.
37. Tseng SY, Otsuji M., Gorski K., Huang X., Slansky JE, Pai SI et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T-cells. J Exp Med 2001; 193: 839-46.
38. Liu X., Gao JX, Wen J., Yin L., Li O., Zuo T. et al. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003; 197: 1083-91.
39. Wandinger KP, Lunemann JD, Wengert O., Bellmann-Strobl J., Aktas O., Weber A. et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003; 361: 2036-43.
40. Avolio C., Filippi M., Tortorella C., Rocca MA, Ruggieri M., Agosta F. et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 2005; 11: 441-6.
41. Muraro PA, Liberati L., Bonanni L., Pantalone A., Caporale CM, Iarlori C. et al. Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol 2004; 150: 123-31.
42. Soilu-Hanninen M., Laaksonen M., Hanninen A., Eralinna JP, Panelius M. Downregulation of VLA-4 on T-cells as a marker of long term treatment response to interferon beta-1a in MS. J Neuroimmunol 2005; 167: 175-82.
43. Fainardi E., Rizzo R., Melchiorri L., Castellazzi M., Govoni V., Caniatti L. et al. Beneficial effect of interferon-beta 1b treatment in patients with relapsingremitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. J Neuroimmunol 2004; 148: 206-11.
44. Boxel-Dezaire AH, Trigt-Hoff SC, Killestein J., Schrijver HM, van Houwelingen JC, Polman CH et al. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment. ? Ann Neurol 2000; 48: 313-22.
45. Rudick RA, Ransohoff RM, Lee JC, Peppler R., Yu M., Mathisen PM et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-1300.
46. Bartosik-Psujek H., Stelmasiak Z. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients. Clin Neurol Neurosurg 2006; 108: 644-7.
47. Wergeland S., Beiske A., Nyland H., Hovdal H., Jensen D., Larsen JP et al. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol 2005; 12: 171-5.
48. Laske C., Oschmann P., Tofighi J., Kuhne BS, Diehl H., Bregenzer T. et al. Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b. Eur Neurol 2001; 46: 210-14.
49. Sellebjerg F., Ross C., Koch-Henriksen N., Sorensen PS, Frederiksen JL, Bendtzen K. et al. CD26 + CD4 + T-cell counts and attack risk in interferon-treated multiple sclerosis. Mult Scler 2005; 11: 641-5.
50. Batocchi AP, Rotondi M., Caggiula M., Frisullo G., Odoardi F., Nociti V. et al. Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol 2003; 139: 150-4.
51. Casoni F., Merelli E., Bedin R., Sola P., Bertolotto A., Faglioni P. Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis. ? Acta Neurol Scand 2004; 109: 61-5.
52. Petzold A., Brassat D., Mas P., Rejdak K., Keir G., Giovannoni G. et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004; 10: 281-3.